Drug intelligence / Profile preview

P-GEMD

Development stage: Unknown
Modality: Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

P-GEMD is a combination chemotherapy regimen comprising pegaspargase, gemcitabine, etoposide, liposomal mitoxantrone hydrochloride, and dexamethasone. It is being investigated for the treatment of untreated early non-upper respiratory tract or advanced extranodal NK/T-cell lymphoma (NKTCL), an aggressive subtype of non-Hodgkin lymphoma. The regimen aims to improve therapeutic efficacy and safety in patients with this challenging disease, particularly those with advanced-stage disease or early-stage non-upper aero-digestive tract involvement who frequently develop hemophagocytic lymphohistiocytosis.

Other names: P-GEMD regimen

Targets

DNA

Beyond the preview

Go deeper on P-GEMD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P-GEMD.

Explore the full profile